| SNC103 / Shanghai Simnova Bio |
NCT05563545: Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia |
|
|
| Completed | 1 | 2 | RoW | CAR-NK-CD19 Cells | Shanghai Simnova Biotechnology Co.,Ltd., Hebei Yanda Ludaopei Hospital | Acute Lymphoblastic Leukemia | 11/22 | 11/22 | | |
NCT04796675: Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies |
|
|
| Recruiting | 1 | 27 | RoW | Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells | Wuhan Union Hospital, China, Shanghai Simnova Biotechnology Co.,Ltd. | Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin's Lymphoma | 03/23 | 03/24 | | |
| Recruiting | 1 | 20 | RoW | After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated. | RenJi Hospital, Shanghai Simnova Biotechnology Co.,Ltd. | Autoimmune Diseases | 01/25 | 12/25 | | |
NCT06206902: F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma |
|
|
| Recruiting | 1 | 55 | RoW | After preconditioning with chemotherapy, F01 will be evaluated. | Shanghai Simnova Biotechnology Co.,Ltd., Wuhan Union Hospital, China | Non-Hodgkin's Lymphoma | 01/25 | 12/25 | | |
NCT06468683: F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 50 | RoW | After preconditioning with chemotherapy, F01 will be evaluated. | Shanghai Simnova Biotechnology Co.,Ltd. | Lupus Erythematosis | 01/27 | 12/27 | | |
